Thomas Albini, MD, discusses the factors that drive his decision to reimplant Retisert®. When treating chronic noninfectious posterior uveitis, reimplantation of RETISERT® may be needed after 2.5-3 years to help ensure management of the disease.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
RETISERT and RETISERT READY are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.